I've never heard of small molecule epigenetic drugs being referred to as gene therapy. Gene therapy is more related to physical changes to the DNA genome, such as with CRISPR, or forced overexpression of a particular gene via a viral approach. BET inhibitors block the ability of BET proteins to bind to, or read, certain acetylated lysine residues. However, BET inhibitors do not alter the DNA.

There are MANY cardiovascular outcome trials ongoing right now that are based on incidence of major adverse cardiac events. In no way does that comment in the article refer explicitly to the BETonMACE trial, or to any CVOT trial for that matter. It seems to be referring to unexpected major adverse event (unexpected side effect, for example) due to a gene therapy intervention.

BDAZ